Drug Discovery World

SEPTEMBER 16, 2022

Here, DDW Editor Reece Armstrong explores the global hubs of innovation for cell and gene therapies. Since the approval of Kymirah in 2017, the cell and gene therapy sector has emerged as an exciting and innovative market, representing some of the most promising drugs the pharmaceutical industry has ever seen. .

Therapies 130

Therapies Clinical Trials Production Trials 130

PLOS: DNA Science

MARCH 21, 2024

The Food and Drug Administration just announced approval of Lenmeldy (atidarsagene autotemcel), a gene therapy to treat the neurological condition metachromatic leukodystrophy (MLD). The history of gene therapy for MLD is compelling – DNA Science covered it for Rare Disease Day in 2021, here. She passed away in 2013.

Therapies 78

Therapies Clinical Trials DNA Trials 78

Drug Discovery World

FEBRUARY 13, 2024

The UK’s Education Secretary Gillian Keegan attended a meeting with the Cell and Gene Therapy Catapult (CGT Catapult) to discuss the role of apprenticeships in the advanced therapies industry. The ATAC programme, which was set up in 2018, is designed to train individuals to work in the advanced therapies industry.

Therapies 130

Therapies International Science Government 130

Drug Target Review

SEPTEMBER 1, 2023

Could you explain the fundamental distinction between autologous and allogeneic cell therapies and how they differ in terms of cell sourcing and application? Autologous immune cell therapy involves the grafting of a patient’s own immune cells. Then, cells are infused back to that same patient.” There are pros and cons to each.

Therapies 105

Therapies Engineering Production Clinical Trials 105

BioPharma Drive: Drug Pricing

JUNE 29, 2023

Sigilon Therapeutics, a biotech that’s been collaborating with Lilly since 2018, has agreed to be bought for up to $310 million in the pharma’s second announced buyout this month.

Therapies 98

Therapies 98

Drug Discovery World

APRIL 22, 2024

The treatment becomes only the second CAR-T cell therapy to secure routine funding for use in the NHS, and the only one for treating ALL in children and young adults under 26 years old.

Doctors 130

Doctors Treatment Hospitals Therapies 130

Drug Discovery World

DECEMBER 18, 2023

Casgevy The committee recommended granting a conditional marketing authorisation for Casgevy (exagamglogene autotemcel), an advanced therapy medicinal product (ATMP) for the treatment of transfusion dependent beta-thalassemia and severe sickle cell disease.

Drugs 130

Drugs Therapies Treatment Disease 130

Drug Target Review

NOVEMBER 7, 2023

To test which patients are more likely to respond to LYTAC therapy, the level of neddylated CUL3 could be measured. Enzyme replacement therapy is a frequent treatment for these disorders. 2018 December [2023 November 1]; 6(24):476. The team also found proteins that block LYTACs from functioning normally. References 1 Sun A.

Therapies 58

Therapies Science Disease Treatment 58

Drug Discovery World

MARCH 12, 2024

Three of these are key to the advancement of gene therapies, cancer research and Parkinson’s treatments.

Laboratories 130

Laboratories Therapies International Treatment 130

PLOS: DNA Science

JUNE 1, 2023

The newest FDA-approved gene therapy treats the severe, skin-peeling condition dystrophic epidermolysis bullosa (DEB). The gene treatment has been a long time coming, but it differs from the handful of other approved gene therapies: it isn’t a one-and-done. DEB has been a candidate for a gene therapy since 2002.

FDA Approval 52

FDA Approval Therapies FDA Disease 52

A Dose of Drug Development

SEPTEMBER 17, 2018

By: Kevin Cho Despite market volatility, 2018 has been on an astounding year for the biotech companies. How Integrium as a company plays a role in advanced technology such as these is that Integrium has the advantage of having 20 years of experience with variety of therapies within its portfolio. BIL and the year is yet to be over.

Marketing 40

Marketing Therapies 40

Drug Discovery World

JULY 14, 2022

Pharmaceutical company SIGA Technologies has announced that its oral therapy tecovirimat has been approved in the UK for the treatment of smallpox, monkeypox, cowpox. . The therapy has also been approved for the treatment of complications following vaccination against smallpox in adults and children with a body weight of at least 13kg. .

Treatment 130

Treatment Pharmaceutical Companies Vaccine Virus 130

Drug Discovery World

SEPTEMBER 15, 2022

A new combination therapy could represent a significant advancement in the treatment of metastatic colorectal cancer. CRC is the second most common cause of cancer mortality, accounting for 881,000 deaths globally in 2018, and patients with metastatic disease have a five-year survival rate of just 11%.

Trials 130

Trials Treatment Clinical Trials Hospitals 130

Drug Discovery World

JUNE 14, 2023

After reviewing results of the DESTINY-Breast04 trial and other studies, the CAP/ASCO panel determined that the current HER2 testing recommendations remain valid to identify all breast cancer patients who might benefit from the full spectrum of HER2 related therapies.

Protein Expression 130

Protein Expression Clinical Trials Trials Laboratories 130

Drug Discovery World

JANUARY 23, 2023

JB : Strand was founded in 2018, and our programmable mRNA technology has broad applicability across a variety of diseases. Our initial focus is to develop mRNA therapies that act through multiple immune mediated mechanisms to deliver potentially curative treatments in oncology. DS: What will 2023 hold for your company?

RNA 246

RNA Engineering Therapies Disease 246

Drug Discovery World

SEPTEMBER 1, 2023

metaLead, which is developing therapies to treat metal-related diseases, currently focused on Wilson disease, lead poisoning, and neurodegeneration with brain iron accumulation. Since its inception in 2018, BII has supported 87 start-ups and projects.

Laboratories 130

Laboratories Disease Therapies Treatment 130

FDA Law Blog: Biosimilars

JUNE 23, 2024

However, the well-intentioned statutory language enacted in 1970 did not anticipate important changes in clinical therapies and advances in medical technology, and in some cases has created obstacles both to ensuring needed patient access and successful medical outcomes. 2] Why is this an issue? Highly concentrated opioid formulations (e.g.,

Nurses 98

Nurses Pharmacy Regulations Therapies 98

Drug Discovery World

MAY 22, 2023

Cell therapy, RNA technology, antibody drug conjugates and AI/machine learning are among the key areas of investment for pharma, according to a new report. While the reported bio partnering deal values for 2022 were the second highest recorded, the number of transactions was the lowest since 2018. Biotech companies raised $16.9

Pharma Companies 130

Pharma Companies RNA Therapies Virus 130

Antidote

JULY 29, 2022

Between 2009 and 2018, U.S. billion to bring a new therapy to market. The process of getting a new drug to market is an expensive one. biopharmaceutical companies spent about $1 billion per drug according to an analysis published in JAMA , and other studies have found that it can cost up to $2.8

Clinical Trials 96

Clinical Trials Trials Pharmaceuticals Therapies 96

Drug Discovery World

DECEMBER 13, 2022

The therapy, known as a bispecific antibody, binds to both T cells and multiple myeloma cells and directs the T cells to kill multiple myeloma cells. The success of talquetamab was even seen in patients whose cancer was resistant to all approved multiple myeloma therapies. Talquetamab was tested in Phase I and Phase II trials.

Clinical Trials 130

Clinical Trials Trials Therapies Clinical Research 130

Drug Discovery World

APRIL 11, 2023

2018; 10 (1): 34‐45 Duchesne M, et al. 2018; 200: 2253–2262. The National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending AstraZeneca’s Tezspire (tezepelumab). International ERS/ATS guidelines on definition, evaluation, and treatment of severe asthma. Eur Respir J. 2014;43:343-373.

Treatment 246

Treatment Clinical Trials Trials Science 246

Drug Discovery World

MAY 15, 2024

Dr Catherine Beech , CEO at Exonate and Dr Pete Adamson , CSO at Breye Therapeutics discuss the need for better therapies to treat diabetic retinal disease and current progress in the field. Selective targeting would enable the therapy to treat the disease whilst not impacting the natural processes of VEGF. Diabetes Res Clin Pract.

Disease 162

Disease Treatment Therapies Pharmaceuticals 162

The Pharma Data

DECEMBER 22, 2020

Tagrisso Approved as Adjuvant Therapy for NSCLC With EGFR Mutations. Tagrisso was approved in 2018 for first-line treatment of patients with metastatic non-small cell lung cancer with EGFR exon 19 deletions or exon 21 L858R mutations. Professional. TUESDAY, Dec. Food and Drug Administration announced Friday.

Therapies 52

Therapies FDA Treatment Disease 52

The Pharma Data

NOVEMBER 9, 2020

Talaris Chief Executive Officer Scott Requadt sees FCR001, the company’s investigational cell therapy, as a potential pipeline in a product (an experimental treatment that could have multiple uses across a number of indications). When that unit dissolved, rights to FCR001 reverted to Regenerex.

Production 52

Production Therapies Disease Treatment 52

Drug Discovery World

JANUARY 17, 2024

This, coupled with a growing understanding of the heterogeneity of cancer as the basis for treatment resistance, tumour evolution and therefore the main source of therapeutic failure, 6 has highlighted the importance of developing personalised therapy. Tumour heterogeneity and resistance to cancer therapies. 15 , 81–94 (2018).

DNA 147

DNA Clinical Trials RNA Treatment 147

Drug Discovery World

DECEMBER 20, 2022

While antibodies must be injected, minibinders can be formulated as oral therapies thanks to their exceptional stability. . Since its inception in 2018, BII has supported 70 start-ups and projects with €59 million. Recent company successes include Adcendo, Stipe Therapeutics, Twelve Bio, Octarine Bio, and Cirqle Biomedical.

Laboratories 130

Laboratories Science International Therapies 130

Drug Discovery World

MAY 15, 2023

Renos Savva, Head of Innovation, Discovery Park Savva’s previous experience includes co-founding Domainex, recognised by the Financial Times in 2018 as the ‘fastest-growing drug discovery contract research organisation in Europe’, and developing and delivering the postgraduate Bio-business programme at Birkbeck University.

Science 130

Science Laboratories Clinical Development Therapies 130

Drug Discovery World

MARCH 6, 2023

METSYSTEM’s unique technology is designed to predict cancer metastasis and determine the optimal chemotherapy to treat it preventively. Amplify Therapeutics: Disease-modifying therapies for Gaucher disease and genetic subgroups of Parkinson’s disease.

Science 130

Science RNA Disease International 130

Drug Target Review

JANUARY 17, 2024

This insight could lead to potential therapies to prevent treatment resistance. The dataset became the largest of its kind, which featured matched tumour samples from 123 glioblastoma patients at diagnosis and then recurrence after initial therapy. World Neurosurgery 2018 August [2024 January 12]; 116:505-17.

Treatment 58

Treatment Therapies Disease Drugs 58

Drug Discovery World

MAY 30, 2023

From antibody-drug conjugates and RNA, to CRISPR and CAR-T therapy, DDW asked the drug discovery industry what the most important development in oncology over the last five years has been. Immunopheresis is a ‘subtractive therapy,’ in contrast to alternative drugs that constitute ‘additive’ therapies.

Research 130

Research Targeted Protein Degradation Drugs RNA 130

Drug Discovery World

FEBRUARY 8, 2023

Svea Cheeseman , Refeyn, explains why better efficiency is needed to advance the production of viral vectors for use in gene therapies. Adeno-associated viruses (AAVs) are a promising, widely used vector for delivering gene therapies. Data were provided by the Cell and Gene Therapy Catapult (London, UK). 2018 Jan 8;8:166-180.

Therapies 130

Therapies Virus Packaging Production 130

Drug Discovery World

JUNE 1, 2023

A market research report published in late June 2018 by HTF market Intelligence Consulting suggested that the ADC market in China would grow exponentially by 2023 4. Varying sources suggest that China has been one to watch over recent years and continues to be going forward.

Marketing 245

Marketing FDA Approval Licensing Licensing 245

Drug Discovery World

JULY 22, 2022

Although immunotherapy has revolutionised cancer therapy, the effectiveness of currently available immunotherapies varies significantly across patients and treatment types. To mitigate these risks, clinicians are turning to other immunomodulators, such as cell-based therapies, bispecific antibodies, and cytokine treatments.

Therapies 130

Therapies Treatment Engineering Clinical Trials 130

Drug Target Review

SEPTEMBER 4, 2023

7,9 Dihydrofolate reductase-thymidylate synthase (DHFR) have been successfully exploited for the therapy of bacterial infections and other parasitic diseases such as malaria. 2018): Ubiquitin Proteasome pathway proteins as potential drug targets in parasite Trypanosoma cruzi, Scientific Reports. (8):8399. link] Ojewale Kayode (2018).

Drugs 110

Drugs RNA DNA Disease 110

Drug Target Review

NOVEMBER 6, 2023

2 It is this complexity that necessitates powerful, targeted combination therapies. 4, 5 More recently, new combination regimens have emerged that incorporate targeted therapies to treat a variety of blood cancers, including multiple myeloma (MM), chronic lymphocytic leukaemia (CLL) and acute myelogenous leukaemia (AML).

Small Molecule 110

Small Molecule Therapies Treatment Immune Response 110

Drug Target Review

DECEMBER 28, 2023

In most cancers, the tumour evolves by acquiring mutations that confer growth advantages or resistance to therapies. However, if the therapy targets only the subclonal (branch) mutations, this will result in the mere ‘pruning’ of specific branches rather than elimination of the whole cancer.

Bioinformatics 104

Bioinformatics Immune Response DNA Vaccine 104

Common Sense for Drug Policy Blog

JANUARY 5, 2024

of the US adult population, injected drugs in 2018. Much of this increase is likely attributable to increases in IDU, but it is important to consider methodological differences in the creation of this 2018 estimate vs the 2011 estimate. million PWID in 2011, which suggest the 2018 estimate is closer to 3 times higher than in 2011.

Drugs 40

Drugs Treatment Disease Therapies 40